ClinicalTrials.gg
CompletedNCT00112346Updated Oct 28, 2015

Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

A Phase 2 interventional study of Cetuximab + platinum + gemcitabine and Platinum + Gemcitabine in Non-Small-Cell Lung Carcinoma, sponsored by Eli Lilly and Company. Completed at 38 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-10-28.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung — 2 open to participants now, 2 under way, none of them phase 3. Cetuximab · Carcinoma, Non-Small-Cell Lung.

Enrollment
11th of 51
120 · median 63
Started
2005
with 11 others
Phase 2
31 of 52
1 open now
Registered
10th of 52
by date
Lead sponsor
13 of 52
Eli Lilly and Company

Among the 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung, this one is the 11th largest by enrollment of the 51 interventional ones that give a count, is one of 12 that started in 2005, is one of 31 in phase 2, and was the 10th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

2 of the 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The primary purpose of this study is to estimate the number of patients with non-small cell lung cancer whose tumor responds to the treatments given in this study.

03

Conditions studied

  • Non-Small-Cell Lung Carcinoma

Keywords

  • Non-Small Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have advanced or non-small cell lung cancer that has not been previously treated with any chemotherapy.
  • Must not have received cetuximab or any medications that target the same pathway as cetuximab (such as Iressa or Tarceva).
  • Must not have had or severe allergic reactions to any monoclonal antibodies and must not have severe restrictive or interstitial lung disease.
  • Must be able to carry out work of light or sedentary nature (e.g. light house work, office work).
  • It must be at least 4 weeks since last major surgery or prior treatment with an product and at least 12 weeks from any radiation therapy to the chest.

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or breastfeeding.
  • Women with a positive pregnancy test on enrollment or prior to study drug administration.
  • Any concurrent (subjects with a previous malignancy but without evidence of disease for 5 years will be allowed to enter the trial).
  • Symptomatic or uncontrolled in the central nervous system (CNS).
  • Peripheral neuropathy.
  • Inadequate hematologic function defined by an (ANC) \<1,500/mm\^3, a count \<100,000/mm\^3, or a level \< 9g/dL.
  • Inadequate liver function.
  • Inadequate kidney function.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants

Study arms

  • Active comparator
    A

    Drug: Cetuximab + platinum + gemcitabine

  • Active comparator
    B

    Drug: Platinum + Gemcitabine

Interventions

  • DrugCetuximab + platinum + gemcitabine

    Drug pages: Cetuximab · Platinum Compounds · Gemcitabine

    Solution, IV, Cetuximab: 400mg/m2 on Day 1 then given weekly at 250mg/m2 starting on Day 8 + Gemcitabine given at 1250mg/m2 (Day 1 \& Day 8 of each cycle) + Cisplatin given at 75mg/m2 or Carboplatin AUC=5, Cycle of therapy is every 3 weeks. Cetuximab is given weekly, Maximum of 6 cycles (18 weeks) Cetuximab will be continued during the period following discontinuation of chemotherapy, until disease progression or cetuximab intolerance.

    Also known as: Erbitux

  • DrugPlatinum + Gemcitabine

    Drug pages: Platinum Compounds · Gemcitabine

    Solution, IV, Gemcitabine given at 1250mg/m2 (Day 1 \& Day 8 of each cycle) + Cisplatin given at 75mg/m2 or Carboplatin AUC=5, Cycle of therapy is every 3 weeks, Maximum of 6 cycles = 18 weeks.

06

What researchers measure

Primary outcomes

  1. tumor response per treatment arm

Secondary outcomes

  1. disease control, symptom response, symptomatic progression, & progression free survival.

07

Study locations

38 sites
  • Local Institution
    Mobile, Alabama, United States
  • Local Institution
    Anchorage, Alaska, United States
  • Local Institution
    Bakersfield, California, United States
  • Local Institution
    Corona, California, United States
  • Local Institution
    Oxnard, California, United States
  • Local Institution
    San Diego, California, United States
  • Local Institution
    Whittier, California, United States
  • Local Institution
    Lakewood, Colorado, United States
  • Local Institution
    Boynton Beach, Florida, United States
  • Local Institution
    Brooksville, Florida, United States
  • Local Institution
    Inverness, Florida, United States
  • Local Institution
    Pembroke Pines, Florida, United States
  • Local Institution
    Austell, Georgia, United States
  • Local Institution
    Honolulu, Hawaii, United States
  • Local Institution
    Skokie, Illinois, United States
  • Local Institution
    Muncie, Indiana, United States
  • Local Institution
    Annapolis, Maryland, United States
  • Local Institution
    Frederick, Maryland, United States
  • Local Institution
    Rockville, Maryland, United States
  • Local Institution
    Plymouth, Massachusetts, United States
  • Local Institution
    Farmington, New Mexico, United States
  • Local Institution
    Armonk, New York, United States
  • Local Institution
    Stony Brook, New York, United States
  • Local Institution
    Gastonia, North Carolina, United States
  • Local Institution
    Wilmington, North Carolina, United States
  • Local Institution
    Bismarck, North Dakota, United States
  • Local Institution
    Cincinnati, Ohio, United States
  • Local Institution
    Portland, Oregon, United States
  • Local Institution
    Charleston, South Carolina, United States
  • Local Institution
    Dallas, Texas, United States
  • Local Institution
    Vancouver, Washington, United States
  • Local Institution
    Edmonton, Alberta, Canada
  • Local Institution
    Moncton, New Brunswick, Canada
  • Local Institution
    Hamilton, Ontario, Canada
  • Local Institution
    Montreal, Ontario, Canada
  • Local Institution
    Toronto, Ontario, Canada
  • Local Institution
    Windsor, Ontario, Canada
  • Local Institution
    Greenfield Park, Quebec, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2005, a primary completion of Dec 2006 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2005
First posted
Jun 2, 2005
Start
Jan 2005
Primary completionActual
Dec 2006
CompletionActual
Dec 2006
Last update
Oct 28, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00112346
Responsible party
Sponsor
First posted
Jun 2, 2005
Start date
Jan 2005
Primary completion
Dec 2006
Completion
Dec 2006
Last update
Oct 28, 2015

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cetuximab · Platinum Compounds · Gemcitabine

Start the discussion